Edge Medical (2675.HK): China Healthcare Corporate Day 2026 Takeaways — solid overseas expansion; procedure volume ramp

Research evidence excerpt

Edge Medical (2675.HK): China Healthcare Corporate Day 2026 Takeaways — solid overseas expansion; procedure volume ramp

parisons between companies in different sectors and markets.

Disclosures

The rating(s) for Edge Medical is/are relative to the other companies in its/their coverage universe: AK Medical, Angelalign Technology, Asymchem

(A), Asymchem (H), China Resources Pharmaceuticals, Edge Medical, Frontage Holdings, Genscript Biotech Corp., Gushengtang Holdings, Hygeia

Healthcare, Jinxin Fertility, MicroPort MedBot, MicroTech Medical, Pharmaron (A), Pharmaron (H), Samsung Biologics Co., Shandong Weigao Group,

Shanghai Pharma, Sinopharm Group, Tigermed (A), Tigermed (H), Tinavi Medical, Topchoice Medical, Venus Medtech Inc., WuXi AppTec Co. (A), WuXi

AppTec Co. (H), WuXi Biologics, WuXi XDC

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, “Goldman Sachs”) and companies covered

by Goldman Sachs Global Investment Research and referred to in this research.

There are no company-specific disclosures for: Edge Medical (HK$34.90)

Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

Rating Distribution Investment Banking Relationships

Buy Hold Sell Buy Hold Sell

Global 50% 34% 16% 65% 60% 45%

As of April 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,074 equity securities. Goldman Sachs assigns stocks as

Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the

purposes of the above disclosure required by the FINRA Rules. See ‘Ratings, Coverage universe and related definitions’ below.